Inventiva announced the appointment of Andrew Obenshain as its new Chief Executive Officer, effective October 1, 2025. Mr. Obenshain will also join the Company’s Board of Directors, succeeding co-founder Frédéric Cren, who has served as CEO since 2012 and is stepping down from both roles.
This leadership transition reflects a strategic decision by the Board to support Inventiva’s next stage of growth and development, with a particular focus on preparing for the potential commercialization of lanifibranor in the United States and building its global footprint. Mr. Cren will work with Mr. Obenshain to ensure a smooth transition of strategic priorities.
Mr. Obenshain brings over 20 years of global leadership experience in drug development, regulatory strategy, and commercialization, having previously served as CEO of bluebird bio (now Genetix Biotherapeutics), where he led the company's transformation into a commercial-stage gene therapy enterprise and secured multiple regulatory approvals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.